Showing 6171-6180 of 9993 results for "".
- ASA Renews Support of SPOTS Programhttps://practicaldermatology.com/news/asa-renews-support-of-spots-program/2461565/The American Skin Association (ASA) announced the renewal of its support for the SPOTS (Sun Protection Outreach Teaching by Students) program. SPOTS is a community outreach program designed to teach students from preschool through high school about the importance of early detectio
- Relief Therapeutics Enrolls First Patients in Proof-of-Concept Trial of Epidermolysis Bullosa Treatmenthttps://practicaldermatology.com/news/relief-therapeutics-enrolls-first-patients-in-proof-of-concept-trial-of-epidermolysis-bullosa-treatment/2461563/Relief Therapeutics announced the first three patients have been enrolled in a proof-of-concept, investigator-initiated study to evaluate RLF-TD011 as a treatment for epidermolysis bullosa (EB). The primary aim of the study will be to assess changes in the skin microbiome (Staphylococcu
- Eye on the AD Pipeline: Dermavant Completes Enrollment of Phase 3 Trials of VTAMA in Adults and Children with ADhttps://practicaldermatology.com/news/eye-on-the-ad-pipeline-dermavant-completes-enrollment-of-phase-3-trials-of-vtama-in-adults-and-children-with-ad/2461561/Dermavant Sciences has completed patient enrollment in its ADORING 1 and 2 Phase 3 clinical trials of VTAMA (tapinarof) cream, 1% for the topical treatment of atopic dermatitis (AD) in adults and children as young as 2 years old. VTAMA cream is a novel, aryl hydrocarbon receptor agonist
- La Roche-Posay Gives Back: Brand Supports USC's Skin of Color and Pigmentary Disorders Research Fellowshiphttps://practicaldermatology.com/news/la-roche-posay-gives-back-brand-supports-uscs-skin-of-color-and-pigmentary-disorders-research-fellowship/2461558/La Roche-Posay is supporting the Skin of Color and Pigmentary Disorders Research Fellowship at the Keck School of Medicine of University of Southern California (USC). The fellowship allows students, between their third and fourth years of medical school, the opportunity to con
- LEO Pharma Announces Positive Phase 3 Trial Results for Delgocitinib Cream in Adults With Chronic Hand Eczema (CHE)https://practicaldermatology.com/news/leo-pharma-announces-positive-phase-3-trial-results-for-delgocitinib-cream-in-adults-with-chronic-hand-eczema-che/2461556/LEO Pharma announced positive results of the DELTA 2 trial, the second of two pivotal phase 3 clinical trials evaluating delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor for the potential treatment of adults with moderate to severe chronic hand eczema (CHE).
- NRS Announces 2023 Rosacea Awareness Month Theme: Give New Treatments Time to Workhttps://practicaldermatology.com/news/nrs-announces-2023-rosacea-awareness-month-theme-give-new-treatments-enough-time-to-work/2461547/This Rosacea Awareness Month, the National Rosacea Society (NRS) is highlighting the importance of consistency and patience when trying new therapies. “Rosacea has no cure, but the signs and symptoms can go into remission through a combination of medical therapy and life
- Candela Launches the All-New Profound Matrix Systemhttps://practicaldermatology.com/news/candela-launches-the-all-new-profound-matrix-system/2461544/Candela is rolling out the all-new Profound Matrix system. This multi-application system features the Sublime, Sublative radiofrequency (RF), and all-new Matrix Pro applicators. The Sublime and Sublative RF applicators deliver bipolar RF treatments that improve the appearance of fine li
- Murad, Active Minds Join Forces to Help Young Adults Stress Lesshttps://practicaldermatology.com/news/murad-active-minds-join-forces-to-help-young-adults-stress-less/2461543/Murad is partnering with Active Minds, a nonprofit supporting mental health awareness and education for young adults. In 2003, Dr. Murad coined the term 'cultural stress', the day-to-day stress of modern living as a major factor contributing to the chronic exhau
- Evelo Biosciences’ Atopic Dermatitis Candidate Misses Primary Endpoint in Phase 2 Trialhttps://practicaldermatology.com/news/evelo-biosciences-atopic-dermatitis-candidate-misses-primary-endpoint-in-phase-2-trial/2461540/Data from first three cohorts of Evelo Biosciences’ EDP1815 Phase 2 trial show the atopic dermatitis drug candidate did not meet the primary endpoint, the company announced on Wednesday. Evelo stated that there was an unusually high placebo response rate in the first three cohorts of the st
- Sirnaomics Accelerates Clinical Development of STP705 for isSCC, BCChttps://practicaldermatology.com/news/sirnaomics-accelerates-clinical-development-of-stp705-for-isscc-bcc/2461535/Sirnaomics Ltd. is advancing the clinical development of STP705 for the treatment of squamous cell carcinoma in situ (isSCC) and basal cell carcinoma (BCC). Based on positive clinical readouts from a Phase IIb study for isSCC and a Phase II study for BCC, Sirnaomics is formul